TY - T1的MRI诊断标准比较多发性硬化症:皮质病变的作用(S45.003) JF -神经学乔-神经学六世- 86 - 16补充SP - S45.003盟保罗Preziosa AU -玛丽亚罗卡盟Sarlota Mesaros AU -诺阿C首页opetti AU -亚历克斯·罗维拉盟Jaume即将有着非盟-伊莲娜Drulovic盟Amgad Droby AU - Frauke氧化锌碘仿糊AU -诺阿花茎甘蓝盟马西莫菲利皮主持Y1 - 2016/04/05 UR - //www.ez-admanager.com/content/86/16_Supplement/S45.003.abstract N2 -目的:测试不同的成像性能的标准,包括皮质病变的评估,发展的多发性硬化症(MS)的多中心队列研究临床孤立综合征(CIS)的病人。背景:自2010年修订的麦当劳的出版标准,新数据的应用MRI诊断女士变得可用。在单中心的一项研究中,添加的评估皮质病变诊断算法已被证明修改导致更高的特异性(菲利皮主持2010)。方法:双反转恢复和大脑和脊髓t2加权和post-contrast t1序列从五个欧洲中心从72年收购了CIS患者3个月和12个月后疾病发作。患者临床随访≥24个月或直到临床的发展定义女士(平均随访24.2个月)。的敏感性,特异性和准确性不同女士说核磁共振发展的标准测试。结果:在随访,65 CIS患者(90 [percnt])女士(临床和/或放射检查)。所有标准的敏感性高(麦当劳2005 83 [percnt],麦当劳2010 92 [percnt],菲利皮主持2010 80 [percnt])。菲利皮主持2010年更高的特异性(67 [percnt])比别人(50 [percnt]麦当劳2005年和2010年)。所有标准的准确性非常高(麦当劳2005 81 [percnt],麦当劳2010 89 [percnt],菲利皮主持2010 79 [percnt])。 Conclusions: Adding the evaluation of cortical lesions improves specificity of the diagnostic criteria preserving sensitivity and accuracy in a multicentric cohort of CIS patients.Disclosure: Dr. Preziosa has nothing to disclose. Dr. Rocca has nothing to disclose. Dr. Mesaros has received personal compensation for activities with Merck-Serono S.A., Novartis, and Bayer Schering Pharma. Dr. Copetti has nothing to disclose. Dr. Rovira has received personal compensation in an editorial capacity for the American Journal of Neuroradiology and Neuroradiology. Dr. Sastre Garriga has nothing to disclose. Dr. Drulovic has nothing to disclose. Dr. Droby has nothing to disclose. Dr. Zipp has received personal compensation for activities with Teva, Novartis, Merck Serono, Bayer, Johnson & Johnson, Ono Pharma, Octapharma, and Sanofi. Dr. Calabrese has nothing to disclose. Dr. Filippi has received personal compensation for activities for consulting services and/or speaking activities from Biogen Idec, Excemed, Novartis, and Teva Pharmaceutical Industries.Thursday, April 21 2016, 6:30 am-8:30 am ER -